Dataset Information


A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.

ABSTRACT: Bispecific antibodies, while showing great therapeutic potential, pose formidable challenges with respect to their assembly, stability, immunogenicity, and pharmacodynamics. Here we describe a novel class of bispecific antibodies with native human immunoglobulin format. The design exploits differences in the affinities of the immunoglobulin isotypes for Protein A, allowing efficient large-scale purification. Using this format, we generated a bispecific antibody, REGN1979, targeting the B cell marker, CD20, and the CD3 component of the T cell receptor, which triggers redirected killing of B cells. In mice, this antibody prevented growth of B cell tumors and also caused regression of large established tumors. In cynomolgus monkeys, low doses of REGN1979 caused prolonged depletion of B cells in peripheral blood with a serum half-life of approximately 14 days. Further, the antibody induced a deeper depletion of B cells in lymphoid organs than rituximab. This format has broad applicability for development of clinical bispecific antibodies.


PROVIDER: S-EPMC4675964 | BioStudies | 2015-01-01T00:00:00Z


REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5582861 | BioStudies
1000-01-01 | S-EPMC4395786 | BioStudies
2011-01-01 | S-EPMC3242841 | BioStudies
1000-01-01 | S-EPMC5016699 | BioStudies
2020-01-01 | S-EPMC6994471 | BioStudies
2017-01-01 | S-EPMC5240641 | BioStudies
2017-01-01 | S-EPMC5297537 | BioStudies
1000-01-01 | S-EPMC4992859 | BioStudies
2020-01-01 | S-EPMC7532213 | BioStudies
1000-01-01 | S-EPMC4250106 | BioStudies